Cargando…
A phase I, randomized, placebo‐controlled study of molnupiravir in healthy Japanese to support special approval in Japan to treat COVID‐19
Molnupiravir (MK‐4482) is an oral prodrug of the antiviral ribonucleoside analog, N‐hydroxycytidine (NHC), which has activity against RNA viruses, including severe acute respiratory syndrome‐coronavirus 2 (SARS‐CoV‐2). We conducted a phase I safety and pharmacokinetic study of molnupiravir in health...
Autores principales: | Nakamura, Keisuke, Fujimoto, Katsukuni, Hasegawa, Chihiro, Aoki, Ikuo, Yoshitsugu, Hiroyuki, Ugai, Hiroyuki, Yatsuzuka, Naoyoshi, Tanaka, Yoshiyuki, Furihata, Kenichi, Maas, Brian M., Wickremasingha, Prachi K., Duncan, Kelly E., Iwamoto, Marian, Stoch, Selwyn A., Uemura, Naoto |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9538808/ https://www.ncbi.nlm.nih.gov/pubmed/36053806 http://dx.doi.org/10.1111/cts.13395 |
Ejemplares similares
-
Assessment of pharmacokinetics, safety, and tolerability following twice‐daily administration of molnupiravir for 10 days in healthy participants
por: Iwamoto, Marian, et al.
Publicado: (2023) -
Molnupiravir: First Approval
por: Syed, Yahiya Y.
Publicado: (2022) -
The Bioequivalence and Effect of Food on the Pharmacokinetics of a Fixed‐Dose Combination Tablet Containing Rosuvastatin and Ezetimibe in Healthy Japanese Subjects
por: Nishida, Chisato, et al.
Publicado: (2019) -
Computational Analysis of Molnupiravir
por: Sharov, Artem V., et al.
Publicado: (2022) -
Molnupiravir for COVID-19
Publicado: (2022)